NCI Definition: A usually aggressive malignant neoplasm arising from the uterine corpus and less often the cervix. It is characterized by the presence of two components: a malignant epithelial component and a sarcomatous component. In the uterine corpus the epithelial component is usually glandular whereas in the cervix is usually non-glandular. Carcinosarcoma of the cervix, although it is aggressive, it may have a better prognosis compared to the uterine corpus carcinosarcoma. 
Uterine carcinosarcomas most frequently harbor alterations in TP53, PIK3CA, KRAS, FBXW7, and CCNE1 .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, PIK3CA Mutation, and FBXW7 Mutation are the most common alterations in uterine carcinosarcoma .
There are 8 clinical trials for uterine carcinosarcoma, of which 8 are open and 0 are completed or closed. Of the trials that contain uterine carcinosarcoma as an inclusion criterion, 2 are phase 1 (2 open), 5 are phase 2 (5 open), and 1 is phase 3 (1 open).
EGFR is the most frequent gene inclusion criterion for uterine carcinosarcoma clinical trials .
Carboplatin, paclitaxel, and selinexor are the most common interventions in uterine carcinosarcoma clinical trials.
Significant Genes in Uterine Carcinosarcoma
EGFR is an inclusion eligibility criterion in 1 clinical trial for uterine carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and uterine carcinosarcoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.